<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">101656080</journal-id>
<journal-id journal-id-type="pubmed-jr-id">43733</journal-id>
<journal-id journal-id-type="nlm-ta">Cell Syst</journal-id>
<journal-id journal-id-type="iso-abbrev">Cell Syst</journal-id>
<journal-title-group>
<journal-title>Cell systems</journal-title>
</journal-title-group>
<issn pub-type="ppub">2405-4712</issn>
<issn pub-type="epub">2405-4720</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29605183</article-id>
<article-id pub-id-type="pmc">5920724</article-id>
<article-id pub-id-type="doi">10.1016/j.cels.2018.03.001</article-id>
<article-id pub-id-type="manuscript">NIHMS955036</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>A systematic evaluation of molecular networks for discovery of disease genes</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Huang</surname>
<given-names>Justin K.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="author-notes" rid="FN2">†</xref>
<xref ref-type="author-notes" rid="FN1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Carlin</surname>
<given-names>Daniel E.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="author-notes" rid="FN2">†</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yu</surname>
<given-names>Michael Ku</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Wei</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kreisberg</surname>
<given-names>Jason F.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tamayo</surname>
<given-names>Pablo</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ideker</surname>
<given-names>Trey</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Bioinformatics and Systems Biology Program, University of California San Diego, La Jolla, CA 92093, USA</aff>
<aff id="A2">
<label>2</label>School of Medicine, University of California San Diego, La Jolla, CA 92093, USA</aff>
<aff id="A3">
<label>3</label>Moores Cancer Center, University of California San Diego, La Jolla, CA 92103, USA</aff>
<aff id="A4">
<label>4</label>Cancer Program, Eli and Edythe Broad Institute of Harvard and MIT, Cambridge MA 02142, USA</aff>
<author-notes>
<corresp id="FN1"><label>*</label>Lead Contact, Corresponding Author. Contact: Justin Huang (<email>jkh013@ucsd.edu</email>)</corresp>
<fn fn-type="equal" id="FN2">
<label>†</label>
<p id="P1">Equal Contribution</p>
</fn>
<fn fn-type="COI-statement" id="FN5">
<p id="P66">
<bold>Declaration of Interests</bold>
</p>
<p id="P67">Trey Ideker is co-founder of Data4Cure, Inc. and has an equity interest. Trey Ideker has an equity interest in Ideaya BioSciences, Inc. The terms of this arrangement have been reviewed and approved by the University of California, San Diego in accordance with its conflict of interest policies.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>28</day>
<month>3</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>28</day>
<month>3</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<day>25</day>
<month>4</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>25</day>
<month>4</month>
<year>2019</year>
</pub-date>
<volume>6</volume>
<issue>4</issue>
<fpage>484</fpage>
<lpage>495.e5</lpage>
<!--elocation-id from pubmed: 10.1016/j.cels.2018.03.001-->
<abstract id="Abs1">
<title>Summary</title>
<p id="P2">Gene networks are rapidly growing in size and number, raising the question of which networks are most appropriate for particular applications. Here, we evaluate 21 human genome-wide interaction networks for their ability to recover 446 disease gene sets identified through literature curation, gene expression profiling, or genome-wide association studies. While all networks have some ability to recover disease genes, we observe a wide range of performance with STRING, ConsensusPathDB and GIANT networks having the best performance overall. A general tendency is that performance scales with network size, suggesting that new interaction discovery currently outweighs the detrimental effects of false positives. Correcting for size, we find that the DIP network provides the highest efficiency (value per interaction). Based on these results we create a parsimonious composite network with both high efficiency and performance. This work provides a benchmark for selection of molecular networks in human disease research.</p>
</abstract>
<abstract abstract-type="graphical" id="Abs2">
<title>eTOC Blurb</title>
<p id="P3">
<graphic orientation="portrait" position="anchor" xlink:href="nihms955036u1.jpg"></graphic></p>
<p id="P4">We evaluate 21 human genome-wide interaction networks for their ability to recover 446 disease gene sets. While all networks can recover disease genes, we observe STRING, ConsensusPathDB and GIANT networks having the best performance overall. Performance scales with network size, suggesting that comprehensive interaction inclusion outweighs the detrimental effects of false positives. We create a parsimonious composite network with both high efficiency and performance. This work provides a benchmark for selection of molecular networks in human disease research.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>